Tag: NF-kB inhibitor
Catabasis’ PolarisDMD clinical trial for edasalonexent completes enrollment
US biopharma company Catabasis Pharmaceuticals has wrapped up enrollment for the phase 3 PolarisDMD clinical trial designed to evaluate edasalonexent, an NF-kB inhibitor, in Duchenne ... Read More